Dysplasia and cancer screening in 21st century

APMIS

Volumn 122, Issue 8, 2014, Pages 674-682

  Khunger, Monica ^a   Kumar, Ujjwal ^b   Roy, Hemant K ^c   Tiwari, Ashish K ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

Biomarker; Cancer screening; Circulating tumor cells; Dysplasia; Genomics; Metabolomics; Personalized medicine; Proteomics

Indexed keywords

BIOLOGICAL MARKER; PROTEIN; TUMOR MARKER;

CANCER GENETICS; CANCER SCREENING; CIRCULATING TUMOR CELL; DISEASE MARKER; DYSPLASIA; GENOMICS; HUMAN; METABOLOMICS; MOLECULAR DIAGNOSIS; NEOPLASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR BIOPSY;

BIOMARKER; CANCER SCREENING; CIRCULATING TUMOR CELLS; DYSPLASIA; GENOMICS; METABOLOMICS; PERSONALIZED MEDICINE; PROTEOMICS;

CYTODIAGNOSIS; EARLY DETECTION OF CANCER; HUMANS; HYPERPLASIA; NEOPLASM PROTEINS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904696300     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12283     Document Type: Review

References (54)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28.
3. Tiwari AK, Roy HK. Progress against cancer (1971-2011): how far have we come? J Intern Med 2012;271:392-9.
4. Yamamoto K, Hayashi Y, Hanada R, Kikuchi A, Ichikawa M, Tanimura M, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 1995;13:2033-8.
5. Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc JM, Brisson LC, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996;348:1682-7.
6. Bessho F. Effects of mass screening on age-specific incidence of neuroblastoma. Int J Cancer 1996;67:520-2.
7. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968;65:281-393.
8. Croswell JM, Kramer BS, Kreimer AR, Prorok PC, Xu JL, Baker SG, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 2009;7:212-22.
9. Wegwarth O, Schwartz LM, Woloshin S, Gaissmaier W, Gigerenzer G. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med 2012;156:340-9.
10. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
11. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-68.
12. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
13. Thomas T, Abrams KA, Robinson RJ, Mayberry JF. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007;25:657-68.
14. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-4.
15. Bernstein CN. ALMs versus DALMs in ulcerative colitis: polypectomy or colectomy? Gastroenterology 1999;117:1488-92.
16. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103:1611-20.
17. Prensner JR, Chinnaiyan AM, Srivastava S. Systematic, evidence-based discovery of biomarkers at the NCI. Clin Exp Metastasis 2012;29:645-52.
18. Kern SE. Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012;72:6097-101.
19. Sawyers CL. The cancer biomarker problem. Nature 2008;452:548-52.
20. Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem? BMC Med 2012;10:87.
21. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
22. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011;4:365-74.
23. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102:1462-7.
24. Srivastava S, Rossi SC. Early detection research program at the NCI. Int J Cancer 1996;69:35-7.
25. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008;100:1432-8.
26. Prensner J.R., Rubin M.A., Wei J.T., Chinnaiyan A.M. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012;4:127rv123.
27. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
28. Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers - blood-based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011;8:142-50.
29. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5:588-99.
30. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, et al. Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 2009;27:2787-92.
31. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010;10:371-8.
32. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
33. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009;276:6880-904.
34. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007;18:868-73.
35. Hudson T.J., Anderson W., Artez A., Barker A.D., Bell C., Bernabe R.R., et al. International network of cancer genome projects. Nature 2010;464:993-8.
36. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61:1659-65.
37. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006;52:1833-42.
38. Kaye FJ. Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther 2009;8:1399-408.
39. Dianxu F, Shengdao Z, Tianquan H, Yu J, Ruoqing L, Zurong Y, et al. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002;25:336-41.
40. Maire F, Micard S, Hammel P, Voitot H, Levy P, Cugnenc PH, et al. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. Br J Cancer 2002;87:551-4.
41. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006;3:e486.
42. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005;11:1219-25.
43. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med 2010;10:123-32.
44. Di Leva G, Croce CM. miRNA profiling of cancer. Curr Opin Genet Dev 2013;23:3-11.
45. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9.
46. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
47. Chen G, Wang J, Cui Q. Could circulating miRNAs contribute to cancer therapy? Trends Mol Med 2013;19:71-3.
48. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007;25:2840-6.
49. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
50. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010; 58:12-8; discussion 20-1.
51. Mavroudis D. Circulating cancer cells. Ann Oncol 2010;21 (Suppl 7):vii95-100.
52. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010;16:398-406.
53. Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X, et al. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer. Int J Biol Markers 2010;25:59-68.
54. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009;6:339-51.